News · Solventum Corporation (SOLV) · Healthcare

Solventum rises after acquisition of ASB Energy Services expands infrastructure capabilities

Session of November 2, 2026 · Published November 3, 2026 · 4 min read

What happened

Solventum (SOLV) rose 4.2% on November 2, 2026, after it completed the acquisition of ASB Energy Services to expand its high-voltage infrastructure capabilities, the company said on GlobeNewsWire.

$82.50$85.00$87.50$90.00Sep 22Oct 1Oct 12Oct 22Nov 2SOLV closing price, last 30 sessionspromtfinance.com$84.75 (+4.2%)
Closing price over the last 30 trading sessions. On November 2, 2026, SOLV closed at $84.75, up 4.2% on the day and 4.5% lower than 30 sessions earlier.

The stock closed at $84.75 and traded at 1.1 times its 20-day average volume, outperforming the Healthcare sector median by 5.8 percentage points.

How big was the move

The session's rise was 2.9 times a typical daily move for the stock, a pattern consistent with a large, mostly company-specific reaction to the acquisition news. Trading volume of 1.1 times its 20-day average suggested the gain drew noticeably higher attention than a routine session.

-2%0%+2%Aug 10Sep 8Oct 5Nov 2SOLV daily moves, last 60 sessions2 std. dev. bandpromtfinance.com
Each bar is one day's price change; the outlined bar is November 2, 2026. A typical daily move over the past year was 1.9%, so the latest move equals 2.2 times that. Moves outside the dashed lines (about 3.8%) are unusual.

Over the last five sessions the stock had fallen 1.2% while the S&P 500 over five sessions fell 1.8%, underlining that the uptick on November 2 followed company news rather than broad market strength. In the past five years the stock had 18 sessions with a gain of at least 4.2%. Twenty trading days later the median result was a gain of 3.0%, and 10 of 18 were higher; those past outcomes are historical observations and not forecasts.

The technical picture

The stock sat 0.9% below its 20-day moving average and 3.7% below its 50-day moving average while remaining 8.1% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock had spent 92 consecutive trading days above the 200-day average.

$70.00$80.00$90.00Oct '25Feb '26May '26Aug '26Nov '26SOLV one-year price and moving averages200-day50-dayPricepromtfinance.com52-week high $92.4452-week low $62.49
Closing price over the past year. SOLV ends the period 8.3% below its 52-week high, below its 50-day average ($88.00) and above its 200-day average ($78.39).

Momentum measures were neutral: the Relative Strength Index (14 days) was 47, inside the neutral range between 30 and 70. The stock was 10.0% below its 52-week high. Over one month the stock fell 3.5% and over three months it fell 3.6%, while over one year it rose 22.3%, which is 11.8 percentage points ahead of the S&P 500. Sixty-day volatility was 23% annualized, lower than 84% of its own readings over five years, implying relatively muted recent price swings compared with its history.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $8.31 billion, a decline of 0.9% from a year earlier. Diluted earnings per share were $8.19, and earnings per share growth from a year earlier rose 277.4%, reflecting a period of recovering profitability.

$0.00$1.0B$2.0BQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26SOLV quarterly revenuepromtfinance.com$2.1B$2.1B$2.1B$2.2B$2.1B$2.0B$2.0B$2.2B
Quarterly revenue by period end. The latest quarter brought $2.2B, 2.2% more than the same quarter a year earlier.

Gross margin was 54.7% versus 54.5% a year earlier, with operating margin at 25.0% versus 9.3% a year earlier, indicating improved operating leverage. Free-cash-flow margin was 1.4% and return on invested capital was 15.9%. The balance sheet showed net debt of 1.9 times EBITDA and the share count over one year decreased by 0.5%.

Valuation measures were modest: the stock traded at 10.3 times trailing earnings and at 11.8 times expected forward earnings. Its free-cash-flow yield was 0.9%. The price-to-earnings multiple is lower than 60% of its own readings over the past five years, where the five-year median is 17.4 times earnings, suggesting a comparatively cheaper entry relative to its historical range.

PromtFinance scores within the sector were mixed: Value 85 (Strong), Growth 31 (Weak), Quality 60 (Neutral), Momentum 68 (Positive), Revisions 65 (Positive) and Stability 83 (Strong). Those rankings portray a stock that looks inexpensive on conventional measures, with solid stability and improving momentum, but limited growth expectations embedded by the market.

Earnings and analyst expectations

Solventum is due to report next on November 5, 2026. Its last report, on August 5, 2026, showed earnings per share of $2.55 against $1.90 expected, 34.2% above estimates, and was part of a streak of 10 consecutive quarters beating estimates. The average surprise over the last four reports was 13.4% above estimates, and the typical two-day reaction after recent reports was the stock rose 0.5%.

$0.00$2.00$4.00$6.00Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26SOLV quarterly earnings per sharepromtfinance.com$0.70$0.18$0.78$0.51$7.22$0.37$0.07$0.53
Diluted earnings per share by quarter. The latest quarter shows $0.53, against $0.51 in the same quarter a year earlier.

There were 12 analysts with ratings on the stock. The consensus rating was Buy, with 75% of those analysts giving the stock a Buy or Strong Buy. The consensus price target was $84.89, 0.2% above the closing price.

What to watch

  • November 5, 2026: next earnings report date.
  • Integration progress and cost savings from the ASB Energy Services acquisition, as disclosed by the company.
  • Any updates to guidance or management commentary tied to high-voltage infrastructure expansion.
  • Changes in net debt or capital allocation that affect the net debt of 1.9 times EBITDA.
  • Analyst revisions to estimates or the consensus price target following the acquisition and upcoming report.

Related stocks

More news from PromtFinance

Related stories from the last 48 hours

ABBVHealthcareNov 2AbbVie falls 2.0% as healthcare sector slides after upbeat quarterly resultsAbbVie fell 2.0% on November 2, 2026, tracking a weaker healthcare sector despite recent stronger-than-expected third-quarter results and an upgraded 2026 outlook.Read the analysis →ABTHealthcareNov 2Abbott rises after positive Amulet 360 study resultsAbbott rose 3.7% on November 2, 2026, after the VERITAS study showed strong Amulet 360 closure and low stroke incidence.Read the analysis →IDXXHealthcareNov 2IDEXX Laboratories jumps 21.8% after beating earnings and raising guidanceIDEXX Laboratories rose 21.8% after reporting stronger-than-expected Q3 results and raising full-year guidance; trading surged on heavy volume.Read the analysis →ABTHealthcareOct 30Abbott Laboratories rises 1.6% as TECTONIC trial posts positive 30-day outcomesAbbott Laboratories rose 1.6% on October 30, 2026, the session coinciding with positive 30-day TECTONIC trial outcomes for its SonicForce IVL system.Read the analysis →KRYSHealthcareNov 2Krystal Biotech falls 11.0% after mixed third-quarter resultsKrystal Biotech fell 11.0% on November 2, 2026, because of its third-quarter results that beat EPS estimates but showed mixed GAAP figures and guidance items.Read the analysis →HIMSHealthcareOct 30Hims & Hers Health falls after law-firm notices ahead of class-action deadlineHims & Hers Health fell 6.7% on October 30, 2026, after law-firm notices reminded investors of a November 2 deadline to join a securities class action.Read the analysis →AXSMHealthcareNov 2Axsome Therapeutics falls 5.8% after quarterly results on November 2, 2026Axsome Therapeutics fell 5.8% on November 2, 2026, because of its third-quarter results that beat EPS estimates but left investors cautious about growth drivers.Read the analysis →